<DOC>
	<DOCNO>NCT00655473</DOCNO>
	<brief_summary>This study assess effect RO4607381 , compare placebo , atherosclerotic plaque patient coronary heart disease ( CHD ) include patient CHD risk factor . After pre-randomisation period positron emission tomography compute tomography ( PET/CT ) MRI conduct , patient randomize receive either RO4607381 600mg po daily , placebo po daily . PET/CT MRI scan take interval study . The anticipated time study treatment 2 year , target sample size 100 individual .</brief_summary>
	<brief_title>A Study Effect RO4607381 Atherosclerotic Plaque Patients With Coronary Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Plaque , Atherosclerotic</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>adult patient , 1875 year age ; CHD , include patient CHD risk factor ; treat appropriately dyslipidemia ; clinically stable . previous exposure cholesteryl ester transfer protein ( CETP ) inhibitor vaccine ; recent ( within 3 month ) clinically significant coronary event , transient ischemic attack cerebrovascular accident ; severe anemia ; uncontrolled hypertension ; poorly control diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>